New Partnership: ARCC joins CCTG trial aimed at protecting cancer patients from COVID-19
The Canadian Cancer Trials Group (CCTG) has launched a new trial focusing on strengthening the immune system in cancer patients, CCTG IC.8: Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure (COV-IMMUNO). Funding and in-kind support, valued at $2.8 million, is being provided by CCTG/the Canadian Cancer Society, BioCanRx, the Ontario Institute for Cancer Research, The Ottawa Hospital Foundation, The Ottawa Hospital Academic Medical Organization, ATGen Canada/NKMax, and Immodulon Therapeutics, the manufacturer of IMM-101. ARCC is proud to join this group of supporters, providing both cash and in-kind contributions to assist with data linkages and economic analyses.
Find our more about this study by clicking here
Leave a ReplyWant to join the discussion?
Feel free to contribute!